A phase I clinical study of Nimorazole as a hypoxic radiosensitizer

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Nimorazole, a 5-Nitromidazole compound has been shown in animal studies to have similar radiosensitizing properties to misonidazole at clinically acceptable dose levels. The drug is well absorbed in humans after oral administration with peak plasma levels occurring around 90 min after ingestion (range 35-135 min) and a plasma half life between 2 and 4.8 hours. Total doses of Nimorazole up to 60 grams given in daily doses with conventional radiation therapy have demonstrated a significant lack of side effects, in particular no demonstrable neurotoxicity.
TidsskriftInternational Journal of Radiation Oncology, Biology, Physics
Sider (fra-til)1765-8
Antal sider4
StatusUdgivet - sep. 1984

Se relationer på Aarhus Universitet Citationsformater

ID: 63367323